Mpox Clade II Remains Risky in a Few U.S. Cities

Since the global mpox outbreak began in May 2022, cases have continued to occur in the United States in 2024.

According to the U.S. CDC's Notes from the Field published on May 23, 2024, after the peak in late 2022, mpox cases declined sharply and remained significantly lower, about 59 cases per week from October 2023 to April 30, 2024.

Most mpox cases in the U.S. are reported in urban centers.

In New York City, there have been 42 mpox cases from April 7, 2024, to May 4, 2024.

The CDC says most new mpox cases occur in unvaccinated persons. However, vaccine breakthrough cases have been confirmed. 

Since October 2023, five people have died from mpox infection.

CDC recommends that persons at risk for mpox exposure who have not previously recovered from mpox complete the 2-dose JYNNEOS® (MVA-BN®, IMVAMUNE®) vaccination.

A meta-analysis of 16 studies published on April 26, 2024, revealed that the JYNNEOS vaccine effectiveness (VE) for one pre-exposure prophylactic vaccination ranged from 35% to 86%, and VE ranged from 66% to 90% (n=5) for two doses.

Bavarian Nordic's JYNNEOS was co-developed with the U.S. Government (BARDA, BioShield) to ensure adult populations can be protected from smallpox.

As of May 2024, healthcare providers in the U.S. can order JYNNEOS through their preferred wholesaler and distribution partners.